Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms: Cheol Min Shin, Nayoung Kim, Hyuk Yoon, Yoon Jin Choi, Ji Hyun Park, Young Soo Park, Dong Ho Lee; Cancer Res Treat. 2022;54(4):1157-1166. Published online January 18, 2022; DOI: https://doi.org/10.4143/crt.2021.997

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate whether MOS methylation can be useful for the prediction of metachronous recurrence after endoscopic resection of gastric neoplasms.
Materials and Methods
From 2012 to 2017, 294 patients were prospectively enrolled after endoscopic resection of gastric dysplasia (n=171) or early gastric cancer (n=123). When Helicobacter pylori was positive, eradication therapy was performed. Among them, 124 patients completed the study protocol (follow-up duration > 3 years or development of metachronous recurrence during the follow-up). Methylation levels of MOS were measured at baseline using quantitative MethyLight assay from the antrum.
Results
Median follow-up duration was 49.9 months. MOS methylation levels at baseline were not different by age, sex, and current H. pylorii infection, but they showed a weak correlation with operative link on gastritis assessment (OLGA) or operative link on gastric intestinal metaplasia assessment (OLGIM) stages (Spearman’s ρ=0.240 and 0.174, respectively; p < 0.05). During the follow-up, a total of 20 metachronous gastric neoplasms (13 adenomas and 7 adenocarcinomas) were developed. Either OLGA or OLGIM stage was not useful in predicting the risk for metachronous recurrence. In contrast, MOS methylation high group (≥ 34.82%) had a significantly increased risk for metachronous recurrence compared to MOS methylation low group (adjusted hazard ratio, 4.76; 95% confidence interval, 1.54 to 14.79; p=0.007).
Conclusion
MOS methylation can be a promising marker for predicting metachronous recurrence after endoscopic resection of gastric neoplasms. To confirm the usefulness of MOS methylation, validation studies are warranted in the future (ClinicalTrials No. NCT04830618).

Citations

Citations to this article as recorded by

DNA methylation in gastric precancerous lesions: Molecular mechanisms and clinical translation
Si-Hui Zeng, Yu-Qi Wu, Wei-Jian Zhang, Yi-Tian Wang, Lin Xu, Shao-Ju Guo
World Journal of Clinical Oncology.2026;[Epub] CrossRef
The methylation signature of hepatocellular carcinoma trajectory based on pseudotime and chronological time for predicting precancerous patients
Kang Li, Chaoran Zang, Yanan Zhao, Dandan Guo, Wanting Shi, Tingting Mei, Ang Li, Yonghong Zhang
The Oncologist.2025;[Epub] CrossRef
Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective
Alessandro Lavoro, Daria Ricci, Giuseppe Gattuso, Federica Longo, Graziana Spoto, Anastasia Cristina Venera Vitale, Maria Chiara Giuliana, Luca Falzone, Massimo Libra, Saverio Candido
Clinical Epigenetics.2025;[Epub] CrossRef
Blood-Based Surveillance Biomarkers for Gastroesophageal Cancers
Neda Dadgar, Muhammad Anees, Christopher Sherry, Hyun Young Park, Erin E. Grayhack, Arul Goel, Alisha F. Khan, Ashten Omstead, David L. Bartlett, Patrick L. Wagner, Ali H. Zaidi
Cancers.2025; 17(21): 3552. CrossRef
Gastric Cancer after Helicobacter pylori Eradication: Characteristics, Diagnosis, and Management
Seokho Myeong, Ilsoo Kim, Donghoon Kang, Yu Kyung Cho, Jae Myung Park
Digestion.2025; : 1. CrossRef
MIR124-3 and NKX6-1 hypermethylation profiles accurately predict metachronous gastric lesions in a Caucasian population
Catarina Lopes, Tatiana C. Almeida, Catarina Macedo-Silva, João Costa, Sofia Paulino, Carmen Jerónimo, Diogo Libânio, Mário Dinis-Ribeiro, Carina Pereira
Clinical Epigenetics.2024;[Epub] CrossRef
Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study
Yun Suk Na, Sang Gyun Kim, Soo-Jeong Cho
Gastric Cancer.2023; 26(2): 298. CrossRef

8,399 View
154 Download
9 Web of Science
7 Crossref

Gynecologic cancer

Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry: Hyeong In Ha, Eun-Gyeong Lee, Jiwon Lim, So-Youn Jung, Yoon Jung Chang, Young-Joo Won, Myong Cheol Lim; Cancer Res Treat. 2021;53(2):541-548. Published online November 18, 2020; DOI: https://doi.org/10.4143/crt.2020.1001

Abstract PDF PubReader ePub

Purpose
A prior history of breast cancer is a risk factor for the subsequent development of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancers. This study aimed to estimate the incidence of secondary POFT malignancy in breast cancer patients and the clinical outcomes of primary and secondary POFT cancer.
Materials and Methods
We searched the Korea Central Cancer Registry to find patients with primary and secondary POFT cancer who had breast cancer in 1999-2017. The incidence rate and standardized incidence ratio were calculated. Additionally, we compared the overall survival of patients with primary and secondary POFT cancer.
Results
Based on the age-standardized rate, the incidence of second primary POFT cancer after breast cancer was 0.0763 per 100,000 women, which increased in Korea between 1999 and 2017. Among the 30,366 POFT cancer patients, 25,721 were primary POFT cancer only, and 493 had secondary POFT cancer after a breast cancer diagnosis. Second primary POFT cancer patients were older at the time of diagnosis (55 vs. 53, p < 0.001) and had a larger proportion of serous histology (68.4% vs. 51.2%, p < 0.001) than patients with primary POFT. There were no differences between the two groups in tumor stage at diagnosis. The 5-year overall survival rates were 60.2% and 56.3% for primary and secondary POFT cancer, respectively (p=0.216).
Conclusion
The incidence of second primary POFT cancer after breast cancer increased in Korea between 1999 and 2017. Besides, second primary POFT cancer patients were diagnosed at older ages and had more serous histology.

Citations

Citations to this article as recorded by

Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations
Yaping Ma, Hui Guo, Yuchen Hao, Bin Song
Discover Oncology.2025;[Epub] CrossRef
Das Ovarialkarzinom: Score-Werte zur Definition von Risikopatientinnen
Eberhard Paul, Sebastian M. Jud
Geburtshilfe und Frauenheilkunde.2024; 84(03): 226. CrossRef
Risk for Second Primary Ovarian Cancer: A Large Population Based on Surveillance, Epidemiology, and End Results Database
Haiyang Hu, Yangsheng Ren, Huixing Li, Tishuo Zhang, Lin Sun
Oncology.2024; 103(8): 748. CrossRef
High-grade pelvic-type serous carcinoma presenting as a breast rash
Mark Weingarten, Michael Weingarten, Tamara Kalir, Angela Lamb
JAAD Case Reports.2022; 20: 20. CrossRef

8,454 View
148 Download
2 Web of Science
4 Crossref

Lymphoma

Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database: Jin Seok Kim, Yanfang Liu, Kyoung Hwa Ha, Hong Qiu, Lee Anne Rothwell, Hyeon Chang Kim; Cancer Res Treat. 2020;52(4):1262-1272. Published online May 4, 2020; DOI: https://doi.org/10.4143/crt.2020.089

Abstract PDF PubReader ePub

Purpose
The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and rates of second primary malignancies (SPM) in these patients are not known. We aimed to describe temporal changes in BNHL epidemiology and SPM incidence in Korea.
Materials and Methods
A retrospective cohort study used claims data from the National Health Insurance Service that provides universal healthcare coverage in Korea. Newly diagnosed patients aged at least 19 years with a confirmed diagnosis of one of six BNHL subtypes (diffuse large cell B-cell lymphoma [DLBCL], small lymphocytic and chronic lymphocytic [CLL/SLL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia [WM]) during the period 2006-2015 were enrolled and followed up until death, dis-enrolment, or study end, whichever occurred first. Patients with pre-existing primary cancers prior to the diagnosis of BNHL were excluded.
Results
A total of 19,500 patients with newly diagnosed BNHL were identified out of 27,866 with non-Hodgkin lymphoma (NHL). DLBCL was the most frequently diagnosed subtype (41.9%-48.4% of NHL patients annually, 2011-2015). Standardized incidence of the six subtypes studied per 100,000 population increased from 5.74 in 2011 to 6.96 in 2015, with most increases in DLBCL, FL, and MZL. The incidence (95% confidence interval) of SPM per 100 person-years was 2.74 (2.26-3.29) for CLL/SLL, 2.43 (1.57-3.58) for MCL, 2.41 (2.10-2.76) for MZL, 2.23 (2.07-2.40) for DLBCL, 1.97 (1.61-2.38) for FL, and 1.41 (0.69-2.59) for WM.
Conclusion
BNHL has been increasingly diagnosed in Korea. High rates of SPM highlight the need for continued close monitoring to ensure early diagnosis and treatment.

Citations

Citations to this article as recorded by

Actualități în managementul limfoamelor non-Hodgkin: profi lul epidemiologic și socioeconomic
Vasile Musteata
Public Health Economy and Management in Medicine.2026; (2(89)): 26. CrossRef
Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis
Jing Wang, Dongming Zhou, Chenglan Lv, Min Zhou, Rongfu Zhou, Yuan Wan
Expert Review of Hematology.2026; 19(8): 957. CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R–CHOP chemotherapy
Kunye Kwak, Yong Park, Byung Soo Kim, Ka-Won Kang
Scientific Reports.2024;[Epub] CrossRef
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults
Mustafa Wasifuddin, Nosakhare Paul Ilerhunmwuwa, Henry Becerra, Narek Hakobyan, Neharika Shrestha, Ifeanyi Nnamdi Uche, Htet Lin, Hesham Abowali, Jin Zheng, Ruchi Yadav, Akriti Pokhrel, Ladan Enayati, Mitchell Hare, Rohan Hehr, Khrystyna Kozii, Bulat Giba
European Journal of Haematology.2024; 113(4): 454. CrossRef
Causal relationship between beta-2 microglobulin and B-cell malignancies: genome-wide meta-analysis and a bidirectional two-sample Mendelian randomization study
Jiuling Li, Yao Wu, Xin Zhang, Xueju Wang
Frontiers in Immunology.2024;[Epub] CrossRef
Secondary malignancies among mantle cell lymphoma patients
Kossi D. Abalo, Karin E. Smedby, Sara Ekberg, Sandra Eloranta, Simon Pahnke, Alexandra Albertsson-Lindblad, Mats Jerkeman, Ingrid Glimelius
European Journal of Cancer.2023; 195: 113403. CrossRef
Epidemiological and Disease Burden Profiles of Leukemias and Malignant Lymphomas: Overview and Trends in the Republic of Moldova and Worldwide
Vasile Musteata
International Journal of Clinical Medicine.2023; 14(02): 79. CrossRef
Treatment of indolent lymphoma
Seong Hyun Jeong
Blood Research.2022; 57(S1): S120. CrossRef
Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
Meejeong Kim, Hee Sang Hwang, Hyungwoo Cho, Dok Hyun Yoon, Cheolwon Suh, Chan Sik Park, Heounjeong Go, Jooryung Huh
Journal of Pathology and Translational Medicine.2021; 55(5): 330. CrossRef
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
Jun Ho Yi, Gyeong-Won Lee, Ji Hyun Lee, Kwai Han Yoo, Chul Won Jung, Dae Sik Kim, Jeong-Ok Lee, Hyeon Seok Eom, Ja Min Byun, Youngil Koh, Sung Soo Yoon, Jin Seok Kim, Jee Hyun Kong, Ho-Young Yhim, Deok-Hwan Yang, Dok Hyun Yoon, Do Hyoung Lim, Won-Sik Lee,
BLOOD RESEARCH.2021; 56(4): 243. CrossRef

16,812 View
618 Download
23 Web of Science
11 Crossref

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only: Su-Jin Shin, Hosub Park, You-Na Sung, Changhoon Yoo, Dae Wook Hwang, Jin-hong Park, Kyu-pyo Kim, Sang Soo Lee, Baek-Yeol Ryoo, Dong-Wan Seo, Song Cheol Kim, Seung-Mo Hong; Cancer Res Treat. 2018;50(4):1175-1185. Published online December 20, 2017; DOI: https://doi.org/10.4143/crt.2017.494

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pancreatic cancer associated double primary tumors are rare and their clinicopathologic characteristics are not well elucidated.
Materials and Methods
Clinicopathologic factors of 1,352 primary pancreatic cancers with or without associated double primary tumors were evaluated.
Results
Of resected primary pancreatic cancers, 113 (8.4%) had associated double primary tumors, including 26 stomach, 25 colorectal, 18 lung, and 13 thyroid cancers. The median interval between the diagnoses of pancreatic cancer and associated double primary tumors was 0.5 months. Overall survival (OS) of pancreatic cancer patients with associated double primary tumors was longer than those with pancreatic cancer only (median, 23.1 months vs. 17.0 months, p=0.002). Patients whose pancreatic cancers were resected before the diagnosis of metachronous tumors had a better OS than patients whose pancreatic cancer resected after the diagnosis of metachronous tumors (48.9 months and 13.5 months, p=0.001) or those whose pancreatic cancers were resected synchronously with non-pancreas tumors (19.1 months, p=0.043). The OS of pancreatic cancer patients with stomach (33.9 months, p=0.032) and thyroid (117.8 months, p=0.049) cancers was significantly better than those with pancreas cancer only (17.0 months).
Conclusion
About 8% of resected pancreatic cancers had associated double primary tumors, and those from the colorectum, stomach, lung, and thyroid were common. Patients whose pancreatic cancer was resected before the diagnosis of metachronous tumors had better OS than those resected after the diagnosis of metachronous tumors or those resected synchronously.

Citations

Citations to this article as recorded by

Manejo multidisciplinario de paciente con neoplasias sincrónicas: reporte de un caso clínico de cáncer de mama y feocromocitoma
Sheila Maria Huertas Tirado, Jose Luis Vargas Mejia, Ciro Espejo Alencastre
Oncología (Ecuador).2026; 36(1): 1. CrossRef
A Case of Simultaneous Overlapping Cancer of the Pancreatic Head and Gastric Body Managed With Pancreaticoduodenectomy and Total Gastrectomy in Two Stages
Mana Kawajiri, Masaki Kimura, Koya Tochii, Toshiya Higashi, Hidetoshi Matsunami
Cureus.2025;[Epub] CrossRef
Laparoscopic Radical Total Gastrectomy and Pancreatosplenectomy for Synchronous Cancer of the Stomach and Pancreas
Motoki Ebihara, Kentoku Fujisawa, Shusuke Haruta, Hironori Uruga, Masaki Ueno
Cureus.2024;[Epub] CrossRef
Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail
G.R. Setdikova, E.A. Stepanova, A.N. Verbovsky, A.V. Semenkov
Pirogov Russian Journal of Surgery.2024; (8): 57. CrossRef
Pancreatoduodenectomy after Ivor-Lewis Santi oesophagectomy with gastric tube reconstruction. An European multicentre experience
Alessandro D. Mazzotta, Pietro Addeo, Benedetto Ielpo, Michael Ginesini, Nicolas Regenet, Ugo Boggi, Philippe Bachellier, Olivier Soubrane
Surgical Oncology.2024; 57: 102144. CrossRef
The importance of hsa-miR-28 in human malignancies
Seyede Fatemeh Hosseini, Setareh Javanshir-giv, Hanieh Soleimani, Homa Mollaei, Farzad Sadri, Zohreh Rezaei
Biomedicine & Pharmacotherapy.2023; 161: 114453. CrossRef
Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
Takahiro Murokawa, Takehiro Okabayashi, Kenta Sui, Motoyasu Tabuchi, Jun Iwata
Surgical Case Reports.2022;[Epub] CrossRef
A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience
Moustafa S. Alhamadh, Rakan B. Alanazi, Sultan T. Algarni, Ahmed Abdullah R. Alhuntushi, Mohammed Qasim Alshehri, Yusra Sajid Chachar, Mohammad Alkaiyat, Fouad Sabatin
Current Oncology.2022; 29(7): 4941. CrossRef
Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review
Daniel Paramythiotis, Georgia Fotiadou, Eleni Karlafti, Ioanna Abba Deka, Georgios Petrakis, Elisavet Psoma, Xanthippi Mavropoulou, Filippos Kyriakidis, Smaro Netta, Stylianos Apostolidis
Diagnostics.2022; 12(11): 2709. CrossRef
Ergebnisse nach Pankreaseingriffen aus Sicht der Betroffenen: Versorgungsforschung der Selbsthilfegruppe „Arbeitskreis der Pankreatektomierten e. V.“
Ioannis Dimopoulos, Gabriele Meyer, Saleem Ibrahim Elhabash, Michele Sorleto, Carsten Gartung, Nils Ewald, Ulrich Klaus Fetzner, Lutz Otto, Friedhelm Möhlenbrock, Waldemar Uhl, Berthold Gerdes
Zeitschrift für Gastroenterologie.2021; 59(03): 214. CrossRef
An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases
Lei Zhang, Xin Long, Zheng-Nan Hu, Yu Wu, Jia Song, Bi-Xiang Zhang, Wei-Xun Chen
Medicine.2021; 100(20): e25785. CrossRef
Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis
Hironori Hayashi, Koji Amaya, Tomokazu Tokoro, Kosuke Mori, Shunsuke Takenaka, Yuya Sugimoto, Yuto Kitano, Toru Kurata, Shunsuke Kawai, Atsushi Hirose, Tomoya Tsukada, Masahide Kaji, Koichi Shimizu, Kiichi Maeda
Molecular and Clinical Oncology.2021;[Epub] CrossRef
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef
Synchronous concomitant pancreatic acinar cell carcin and gastric adenocarcinoma: A case report and review of literature
Tian Fang, Ting-Ting Liang, Yi-Zhuo Wang, Hai-Tao Wu, Shu-Han Liu, Chang Wang
World Journal of Clinical Cases.2021; 9(28): 8509. CrossRef
A novel long non‑coding RNA TTN‑AS1/microRNA‑589‑5p/FOXP1 positive feedback loop increases the proliferation, migration and invasion of pancreatic cancer cell lines
Jing Zhao, Fang Wu, Jun Yang
Oncology Letters.2021;[Epub] CrossRef
Multiple primary gastrointestinal tumors of gastric, pancreatic and rectal origin; a case report
Abdullah Mohammed Aloraini, Hadeel Ayman Helmi, Nadia Abdulaziz Aljomah, Ahmad Mohmmed Zubaidi
International Journal of Surgery Case Reports.2021; 89(C): 106610. CrossRef
A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
International Journal of Thyroidology.2021; 14(2): 175. CrossRef
Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression
Qing Han, Junhe Li, Jianping Xiong, Zhiwang Song
Journal of Experimental & Clinical Cancer Research.2020;[Epub] CrossRef
Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
Oronzo Brunetti, Giuseppe Badalamenti, Simona De Summa, Angela Calabrese, Antonella Argentiero, Livia Fucci, Vito Longo, Domenico Galetta, Pia Maria Soccorsa Perrotti, Rosamaria Pinto, Daniela Petriella, Katia Danza, Stefania Tommasi, Francesco Leonetti,
Cancers.2019; 11(6): 749. CrossRef

18,215 View
257 Download
17 Web of Science
19 Crossref

Risk of Second Primary Cancer in People with Non-melanoma Skin Cancer: A Nationwide Cohort Study: Shu-Hui Wang, Ching-Chi Chi, Zi-Hao Zhao, Tao-Hsin Tung; Cancer Res Treat. 2018;50(2):428-435. Published online May 10, 2017; DOI: https://doi.org/10.4143/crt.2017.110

Abstract PDF PubReader ePub

Purpose
Previous western studies have found Caucasians with skin cancer, either melanoma or nonmelanoma skin cancer (NMSC), have an elevated risk of second primary cancer. Our objective was to assess the risk of second primary cancer in Taiwanese with NMSC.
Materials and Methods
By using data from Taiwan’s National Health Insurance Research Database, we conducted a population-based cohort study to assess the risk of incident second primary cancer in Taiwanese affected by NMSC.
Results
We identified 505 subjects with NMSC and 2,020 matched controls. After adjustment for potential confounders including age, sex, urbanization, and Charlson Comorbidity Index, people who had NMSC had a 1.43-fold (95% confidence interval [CI], 1.05 to 1.96) risk for the development of second primary cancer as comparedwith control group. Menwith NMSC had a 2.99-fold (95% CI, 1.00 to 9.10) risk for second primary cancer involving the lip, oral cavity, and pharynx and a 3.51-fold (95% CI, 1.21 to 10.17) risk for second primary cancer involving the genitourinary organs when compared to the control group. By contrast, women with NMSC did not have an increased risk of second primary cancer.
Conclusion
This study revealed Asians with NMSC have an increased risk of second primary cancer. Our findings can be a useful reference for health care for people diagnosed with NMSC.

Citations

Citations to this article as recorded by

Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review
Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan
Leukemia Research.2024; 147: 107610. CrossRef
Non‐melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population‐based cohort study
S.J. Yun, J.M. Bae, H. Kim, B.C. Park, J.S. Kim, S.H. Seo, H.H. Ahn, D.Y. Lee, Y.C. Kim, H.J. Park, K.Y. Chung
Journal of the European Academy of Dermatology and Venereology.2020; 34(4): 746. CrossRef

13,355 View
173 Download
2 Web of Science
2 Crossref

Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study: Jae Young Joung, Whi-An Kwon, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won; Cancer Res Treat. 2018;50(1):293-301. Published online April 19, 2017; DOI: https://doi.org/10.4143/crt.2016.543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Secondary primary cancers (SPCs) commonly arise in patients with renal cell carcinoma (RCC). We designed the present study to estimate the SPC incidence in Korean patients with RCC.
Materials and Methods
The study cohort was population-based and consisted of 40,347 individuals from the Korean Central Cancer Registry who were diagnosed with primary renal cancer between 1993 and 2013. Standardized incidence ratios (SIRs) for SPCs were estimated for different ages at diagnosis, latencies, diagnostic periods, and treatments.
Results
For patients with primary RCC, the risk of developing a SPC was higher than the risk of developing cancer in the general population (SIR, 1.13; 95% confidence interval, 1.08 to 1.18). Most cancer types showed higher incidences in patients with RCC than in the general population. However, the relative incidence of gastric cancer as an SPC varied by age. Gastric cancer incidence was elevated in young patients (< 30 years) with RCC, but reduced in older (≥ 30) patients with RCC. Patients with advanced RCC died prematurely, regardless of SPC development. In contrast, those with early-stage RCC survived for longer periods, although SPC development affected their post-RCC survival. After SPC development, women had better survival than men.
Conclusion
In Korean patients with primary RCC, the incidence of SPC was 13% higher than the incidence of cancer in the general population. These findings may play important roles in the conduct of follow-up evaluations and education for patients with RCC.

Citations

Citations to this article as recorded by

Risk of developing subsequent primary breast cancer among non-breast cancer survivors: a retrospective cohort study
Yibing Ruan, Hannah Harsanyi, Matthew T. Warkentin, Huiming Yang, Sasha Lupichuk, Patricia A. Tang, Kareem Jamani, Robert J. Hilsden, Darren R. Brenner, Winson Y. Cheung, Dylan E. O’Sullivan
Breast Cancer.2026;[Epub] CrossRef
Next-generation sequencing identifies the mutational signature of double primary and metastatic malignancies: A case report
Shiying Tang, Yixiao Deng, Yinan Yan, Jie Bai, Huiying He, Shudong Zhang, Jie Yang, Min Qiu, Xiaojun Tian
Current Urology.2025; 19(5): 359. CrossRef
Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status
Sara Nofal, Edwin J Ostrin, Jianjun Zhang, Jia Wu, Paul Scheet, Mara B. Antonoff, John V Heymach, Iakovos Toumazis
International Journal of Cancer.2025; 157(5): 941. CrossRef
Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis
Samuel Tundealao, Praise Okunlola, Tolulope Titiloye, Bolatito Mayungbo, Abiodun Adegbesan, Anusha Sajja, Olajumoke Olarewaju
International Urology and Nephrology.2025; 58(4): 1161. CrossRef
Renal cell carcinoma and risk of second primary cancer: A Danish nationwide cohort study
Maria B. Bengtsen, Dóra K. Farkas, Henrik T. Sørensen, Mette Nørgaard
Cancer Medicine.2024;[Epub] CrossRef
Chance, ignorance, and the paradoxes of cancer: Richard Peto on developing preventative strategies under uncertainty
George Davey Smith, Albert Hofman, Paul Brennan
European Journal of Epidemiology.2023; 38(12): 1227. CrossRef
Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
Frontiers in Surgery.2022;[Epub] CrossRef
Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database
Hong Liu, Xin Heng, Yuan Tian, Zhongming Yang
Scientific Reports.2022;[Epub] CrossRef
Being Precise About Precision Mental Health
Peter Szatmari, Ezra Susser
JAMA Psychiatry.2022; 79(12): 1149. CrossRef
Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
Guoqiao Zheng, Kristina Sundquist, Jan Sundquist, Tianhui Chen, Asta Försti, Otto Hemminki, Kari Hemminki
European Urology Open Science.2021; 24: 52. CrossRef
miR‐34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis
Huaiguo Wu, Xike Zhou, Xuedong Wang, Wei Cheng, Xinjia Hu, Yueping Wang, Bing Luo, Wenjun Huang, Juan Gu
Journal of Cellular and Molecular Medicine.2021; 25(4): 1896. CrossRef
Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy—Who Is at the Greatest Risk?
Lily N. Trinh, Andrew R. Crawford, Mohammad H. Hussein, Mourad Zerfaoui, Eman A. Toraih, Gregory W. Randolph, Emad Kandil
Cancers.2021; 13(6): 1402. CrossRef
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Lucie Pehalova, Denisa Krejci, Jana Halamkova, Lenka Smardova, Lenka Snajdrova, Ladislav Dusek
Cancer Epidemiology.2021; 72: 101929. CrossRef
Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data
Haeyoung Kim, Won Park, Su SSan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi
Radiation Oncology Journal.2021; 39(2): 107. CrossRef
The Risk and Prognosis of Secondary Primary Malignancy in Lung Cancer: A Population-Based Study
Jia Hong, Rongrong Wei, Chuang Nie, Anastasiia Leonteva, Xu Han, Xinyu Du, Jing Wang, Lin Zhu, Wenjing Tian, Haibo Zhou
Future Oncology.2021; 17(33): 4497. CrossRef
Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy
Xi Tian, Wen-Hao Xu, Jun-Long Wu, Hua-Lei Gan, Hong-Kai Wang, Wei-Jie Gu, Yuan-Yuan Qu, Hai-Liang Zhang, Ding-Wei Ye
Pathology and Oncology Research.2021;[Epub] CrossRef
Primary Adenocarcinoma of Lung with Synchronous Renal Cell Carcinoma: A Case Report and Review of the Literature
Sharareh Seifi, Zahra Esfahani-Monfared, Mihan Pourabdollah, Sara Haseli
International Journal of Cancer Management.2020;[Epub] CrossRef
Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry
Seung-Ki Min, Sung Weon Choi, Jiwon Lim, Joo Yong Park, Kyu-Won Jung, Young-Joo Won
Oral Oncology.2019; 95: 16. CrossRef
Post–Modern Epidemiology: When Methods Meet Matter
George Davey Smith
American Journal of Epidemiology.2019; 188(8): 1410. CrossRef
Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis
Mierxiati Abudurexiti, Jun Wang, Ning Shao, Fang-Ning Wan, Wen-Kai Zhu, Bo Dai, Yao Zhu, Ding-Wei Ye
SN Comprehensive Clinical Medicine.2019; 1(11): 900. CrossRef
Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea
Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won
BMC Cancer.2018;[Epub] CrossRef

14,658 View
278 Download
22 Web of Science
21 Crossref

Oncologists’ Experience with Patients with Second Primary Cancer and the Attitudes toward Second Primary Cancer Screening: A Nationwide Survey: Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Boram Park, BeLong Cho, Hyung Jin Kim, Young Jun Lee, Deog-Yeon Jo, Jong Hyock Park; Cancer Res Treat. 2015;47(4):600-606. Published online February 12, 2015; DOI: https://doi.org/10.4143/crt.2014.162

Abstract PDF PubReader ePub

Purpose
Screening for second primary cancer (SPC) is one of the key components to survivorship care. We aim to evaluate the oncologists’ experience with SPCs and assess the current practice, perceived barriers, and recommendations related to SPC screening. Materials and Methods A nationwide survey was conducted with a representative sample of 496 Korean oncologists. A questionnaire based on the findings from our previous qualitative study was administered. Results More than three-fourths of oncologists (76.3%), who participated in the study, had experience with SPC patients. Over half of them (51.9%) stated that it was an embarrassing experience. While the current management practice for SPC varies, most oncologists (80.2%) agreed on the necessity in proactively providing information on SPC screening. A short consultation time (52.3%), lack of guidelines and evidence on SPC screening (47.7%), and patients’ lack of knowledge about SPCs (45.1%) or SPC screening (41.4%) were most frequently reported as barriers to providing appropriate care for managing SPC. Oncologists recommended the development of specific screening programs or guidelines in accordance to the type of primary cancer (65.9%), the development of an internal system for SPC screening within the hospital (59.7%) or systematic connection with the national cancer screening program (44.3%), and education of oncologists (41.4%) as well as patients (48.9%) regarding SPC screening. Conclusion Many oncologists reported the occurrence of SPC as an embarrassing experience. Given the variations in current practice and the lack of consensus, further studies are warranted to develop the optimal clinical strategy to provide SPC screening for cancer survivors.

Citations

Citations to this article as recorded by

Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time‐Varying Effects and Cox Proportional Hazard Analyses
Akikazu Kobori, Chiyoko Makita, Osamu Tanaka, Sunaho Okada, Yuichi Kajiura, Nansei Yamada, Masayuki Matsuo
Asia-Pacific Journal of Clinical Oncology.2026; 22(2): 233. CrossRef
Colorectal Cancer Screening Among Noncolorectal Cancer Survivors: A Systematic Review and Meta-Analysis
Sanjeev Bista, Momtafin Khan, Reynaldo Nambayan, Marcus Vaska, Yibing Ruan, Robert J. Hilsden, Darren R. Brenner, Dylan E. O’Sullivan
American Journal of Preventive Medicine.2026; 70(5): 108239. CrossRef
Breast Cancer Screening among Cancer Survivors: A Systematic Review and Meta-analysis
Sanjeev Bista, Hannah Harsanyi, Momtafin Khan, Reynaldo Nambayan, Marcus Vaska, Yibing Ruan, Robert J. Hilsden, Darren R. Brenner, Dylan E. O’Sullivan
Cancer Epidemiology, Biomarkers & Prevention.2026; 35(4): 506. CrossRef
Cardiovascular risk and undertreatment of dyslipidemia in lung cancer survivors: A nationwide population-based study
In Young Cho, Kyungdo Han, Dong Wook Shin, Sang Hyun Park, Dong Woog Yoon, Sujeong Shin, Su-Min Jeong, Jong Ho Cho
Current Problems in Cancer.2021; 45(1): 100615. CrossRef
Developing an instrument to assess cancer patient preparedness for transition to survivorship care in Korea
Jung‐won Lim
Asian Social Work and Policy Review.2020; 14(3): 172. CrossRef
Second Primary Cancer after Treating Gastrointestinal Cancer
Jeong Youp Park
The Korean Journal of Gastroenterology.2019; 74(4): 193. CrossRef
A national survey of lung cancer specialists’ views on low-dose CT screening for lung cancer in Korea
Dong Wook Shin, Sohyun Chun, Young Il Kim, Seung Joon Kim, Jung Soo Kim, SeMin Chong, Young Sik Park, Sang-Yun Song, Jin Han Lee, Hee Kyung Ahn, Eun Young Kim, Sei Hoon Yang, Myoung Kyu Lee, Deog Gon Cho, Tae Won Jang, Ji Woong Son, Jeong-Seon Ryu, Moon-J
PLOS ONE.2018; 13(2): e0192626. CrossRef
The Dyadic Effects of Family Cohesion and Communication on Health-Related Quality of Life: The Moderating Role of Sex
Jung-won Lim, En-jung Shon
Cancer Nursing.2018; 41(2): 156. CrossRef
Physicians’ attitudes towards the media and peer-review selection of the ‘best cancer doctor’: comparison of two different selection methods
Dong Wook Shin, Juhee Cho, Hyung Kook Yang, So Young Kim, Soohyeon Lee, Eun Joo Nam, Joo Seop Chung, Jeong-Soo Im, Keeho Park, Jong Hyock Park
BMJ Open.2018; 8(5): e019067. CrossRef

12,561 View
93 Download
8 Web of Science
9 Crossref

Metachronous Double Primary Cancer after Treatment of Breast Cancer: Jin Young Kim, Hong Suk Song; Cancer Res Treat. 2015;47(1):64-71. Published online October 27, 2014; DOI: https://doi.org/10.4143/crt.2013.215

Abstract PDF PubReader ePub

Purpose
The pattern of double primary cancer after treatment for breast cancer is important for patient survival.
Materials and Methods
We analyzed 108 cases of metachronous double primary cancer in breast cancer patients treated from 1999 to 2012.
Results
Metachronous double primary cancers occurred in 108 of 2,657 patients (4.1%) with breast cancer. The median time to the occurrence of second cancer after diagnosis of the first was 58.4±41.2 months (range, 6.9 to 180.2 months). The most common cancer was thyroid cancer, which occurred in 45 patients (41.7%). This was followed by gastric cancer in 16 patients (14.8%), endometrial cancer in 10 patients (9.3%), and cervical cancer in seven patients (6.5%). The relative risk showed a significant increase in endometrial (4.78; 95% confidence interval [CI], 1.66 to 13.79), gastric (2.61; 95% CI, 1.68 to 4.06), and thyroid cancer (1.95; 95% CI, 1.37 to 2.79). At 5 years after diagnosis of breast cancer, secondary cancer occurred in 48 patients (44.4%), with 50.0% of the endometrial, 56.3% of the stomach, and 37.8% of the thyroid cancer cases being diagnosed after 5 years. Median survival after diagnosis of the second cancer was 123.9±11.2 months. The prognosis was mainly influenced by the anatomic site.
Conclusion
The incidence of endometrial, stomach, and thyroid cancer increased significantly after treatment with primary breast cancer, and survival was dependent on early detection and the type of second primary cancer. A prolonged follow-up examination for metachronous double primary cancer is needed to provide early detection and improve survival time in patients with breast cancer.

Citations

Citations to this article as recorded by

Overall survival of patients with second primary breast cancer associated with molecular subtype and epidemiological profile at a cancer center
Ariane Silva da Rocha, Gisele Aparecida Fernandes, Cynthia Aparecida Bueno de Toledo Osório, Ruffo de Freitas Junior, Maria Paula Curado
Breast Cancer.2026; 33(1): 62. CrossRef
Secondary Cancer Risk in Breast Cancer with and without Radiotherapy: The Observational Health Data Sciences and Informatics (OHDSI) Cohort Study
Seok Kim, Dachung Boo, Sooyoung Yoo, Borham Kim, Kyubo Kim, Kwangsoo Kim, Eunhye Song, Junmo Kim, Hyun Gee Ryoo, Jin Chul Paeng, In Young Choi, SooJeong Ko, Ie Ryung Yoo, Rae Woong Park, Ho-Young Lee
Cancer Research and Treatment.2026; 58(2): 481. CrossRef
Synchronous Nasopharyngeal Carcinoma and Rectal Adenocarcinoma Treated With Integrated Multimodal Therapy: A Case Report and Literature Review
Najd S AlGazlan, Ali AlFakeeh, Mohammed AlDohan, Ali M AlZahrani
Cureus.2026;[Epub] CrossRef
Risk Factors and Prognostic Implications in Synchronous Breast-Thyroid Dual Primary Cancers: A Matched Case-Control Study
Tao Li, Bin Lu, Yantao Zhang, Peng Zhang, Jun Qi, Yong Sun
Cancer Management and Research.2025; Volume 17: 997. CrossRef
Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations
Yaping Ma, Hui Guo, Yuchen Hao, Bin Song
Discover Oncology.2025;[Epub] CrossRef
Beyond the skin: A case report of vaginal melanoma
Ana-Maria Sandu, Oana Mirela Tiucă, Mihai Emil Căpâlnă, Liliana Maria Chira, Cezara-Anca-Denisa Moldovan, Alexandra-Maria Pop, Silviu Horia Morariu
Acta Marisiensis - Seria Medica.2025; 71(4): 383. CrossRef
Deciphering the Patterns of Dual Primary Cases Registered at the Hospital-Based Cancer Registry: First Experience from Rural Cancer Center in North India
Sankalp Sancheti, Alok Kumar Goel, Anshul Singla, Kuldeep Singh Chauhan, Kiran Arora, Debashish Chaudhary, Tapas Dora, Shweta Tahlan, Prithviraj Kadam, Prachi Joshi, Akash Sali, Rahatdeep Singh Brar, Atul Budukh, Ashish Gulia, Jigeeshu Vasishtha Divatia,
Journal of Laboratory Physicians.2023; 15(04): 524. CrossRef
Multiple synchronous primary malignant neoplasms: A case report and literature review
Linlin Hao, Lihui Zhang, Chuanjie Xu, Min Jiang, Geyi Zhu, Jie Guo
Oncology Letters.2023;[Epub] CrossRef
Association between Thyroid Cancer and Breast Cancer: Two Longitudinal Follow-Up Studies Using a National Health Screening Cohort
Young Ju Jin, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim, Hyo Geun Choi
Journal of Personalized Medicine.2022; 12(2): 133. CrossRef
Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report
Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
BMC Gastroenterology.2021;[Epub] CrossRef
Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics
Lwando Mampunye, Nerina C. van der Merwe, Kathleen A. Grant, Armand V. Peeters, Rispah Torrorey-Sawe, David J. French, Kelebogile E. Moremi, Martin Kidd, Petrus C. van Eeden, Fredrieka M. Pienaar, Maritha J. Kotze
Frontiers in Oncology.2021;[Epub] CrossRef
The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study
Cristina Marinela Oprean, Larisa Maria Badau, Robert-Alexandru Han, Teodora Hoinoiu, Gabriel-Mugur Dragomir, Daciana Grujic, Tiberiu Dragomir, Alis Dema
Diagnostics.2021; 11(11): 1957. CrossRef
High Incidence and Prevalence of Papillary Thyroid Cancer in Breast Cancer Patients
Jung Ho Park, Sanghwa Kim, Lee Su Kim
Journal of Endocrine Surgery.2020; 20(4): 88. CrossRef
Gastric Complications after Adjuvant Radiotherapy for Breast Cancer
Won Kyung Cho, Doo Ho Choi, Won Park, Haeyoung Kim, Seonwoo Kim, Myung-Hee Shin, Hyejung Cha
Journal of Breast Cancer.2019; 22(3): 464. CrossRef
Clinical Characteristics and Prognosis Associated with Multiple Primary Cancers in Breast Cancer Patients
Bong Kyun Kim, Se Jeong Oh, Jeong-Yoon Song, Han-Byoel Lee, Min Ho Park, Yongsik Jung, Woo-Chan Park, Jina Lee, Woo Young Sun
Journal of Breast Cancer.2018; 21(1): 62. CrossRef
Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody
Fumi Saito, Hideaki Shimada, Hideaki Ogata, Takafumi Otsuka, Tetsuo Nemoto, Kazutoshi Shibuya, Hironori Kaneko
Esophagus.2017; 14(4): 366. CrossRef
Metachronous double primary cancer of epithelial and mesenchymal origins
Hongzeng Wu, Ze Li, Helin Feng, Jinming Zhang
Medicine.2017; 96(49): e9036. CrossRef
Development of second primary cancer in Korean breast cancer survivors
Hong Kyu Jung, Suyeon Park, Nam Won Kim, Jong Eun Lee, Zisun Kim, Sun Wook Han, Sung Mo Hur, Sung Young Kim, Cheol Wan Lim, Min Hyuk Lee, Jihyoun Lee
Annals of Surgical Treatment and Research.2017; 93(6): 287. CrossRef
Multiple primary tumours: challenges and approaches, a review
Alexia Vogt, Sabine Schmid, Karl Heinimann, Harald Frick, Christian Herrmann, Thomas Cerny, Aurelius Omlin
ESMO Open.2017; 2(2): e000172. CrossRef
Secondary gastric cancer malignancies following a breast cancer diagnosis: A population-based analysis
Alyson L. Mahar, Daniel J. Kagedan, Julie Hallet, Natalie G. Coburn
The Breast.2017; 33: 34. CrossRef
Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer
Li Zhang, Yansheng Wu, Fangfang Liu, Li Fu, Zhongsheng Tong
Oncotarget.2016; 7(32): 52450. CrossRef
Radiotherapy did not increase thyroid cancer risk among women with breast cancer: A nationwide population‐based cohort study
Li‐Min Sun, Cheng‐Li Lin, Ji‐An Liang, Wen‐Sheng Huang, Chia‐Hung Kao
International Journal of Cancer.2015; 137(12): 2896. CrossRef
A Possible Association Between Thyroid Cancer and Breast Cancer
Jee Hyun An, Yul Hwangbo, Hwa Young Ahn, Bhumsuk Keam, Kyu Eun Lee, Wonshik Han, Do Joon Park, In Ae Park, Dong-Young Noh, Yeo-Kyu Youn, Bo Youn Cho, Seock-Ah Im, Young Joo Park
Thyroid®.2015; 25(12): 1330. CrossRef

17,472 View
121 Download
28 Web of Science
23 Crossref

Case Report

Angiomatoid Fibrous Histiocytoma as a Second Tumor in a Young Adult with Testicular Cancer: Han-Sang Lee, Taewan Kim, Jin-Sook Kim, Hye Ran Lee, Mee Joo, Ji Yeon Park, Seong Yoon Yi; Cancer Res Treat. 2013;45(3):239-243. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.239

Abstract PDF PubReader ePub

Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor, with a low-grade malignant potential, occurring predominantly in children and young adults. Association between AFH and other malignancies has been rarely reported. A 27-year-old man who presented with a palpable abdominal mass was diagnosed as having testicular cancer with multiple liver and lung metastases. At 16 months after chemotherapy, a follow-up computed tomographic scan revealed a supraclavicular mass measuring 3 cm in size, which was suspected to be a recurrence. The patient underwent surgical excision, and the mass was pathologically diagnosed as a AFH. The patient has had no local recurrence and no distant metastasis for 12 months after resection. To the best of our knowledge, this is the first case report of AFH as a second tumor in a patient with testicular cancer.

Citations

Citations to this article as recorded by

Angiomatoid fibrous histiocytoma in the spinal canal of T3-T4: a case report and literature review
Jiangwei Ding, Gang Zhou, Yang Dong, XinXiao Li, Lei Wang, Baorui Guo, Caibin Gao, Siying Xu, Feng Wang, Tao Sun
British Journal of Neurosurgery.2023; 37(5): 1069. CrossRef
Endobronchial Primary Pulmonary Angiomatoid Fibrous Histiocytoma in a Patient with Testicular Germ Cell Tumor: An Evidence Against Somatic Transformation
Mehmet Çetin, Kubra Katipoglu, İlteriş Türk, Şeref Özkara, Kemal Kosemehmetoglu, Pınar Bıçakçıoğlu
International Journal of Surgical Pathology.2022; 30(6): 662. CrossRef
Angiomatoid Fibrous Histiocytoma: Case Presentation with Review of Literature
Gerardo Cazzato, Anna Colagrande, Antonietta Cimmino, Mariella Silecchia, Teresa Lettini, Leonardo Resta, Giuseppe Ingravallo
Osteology.2021; 1(3): 112. CrossRef
Primary angiomatoid fibrous histiocytoma of the lung with mediastinal lymph node metastasis
Chee Kiang Tay, Mariko Siyue Koh, Angela Takano, Marie Christine Aubry, William R. Sukov, Andrew L. Folpe
Human Pathology.2016; 58: 134. CrossRef
Angiomatoid Fibrous Histiocytoma: The Current Status of Pathology and Genetics
Khin Thway, Cyril Fisher
Archives of Pathology & Laboratory Medicine.2015; 139(5): 674. CrossRef
Imaging of childhood angiomatoid fibrous histiocytoma with pathological correlation
Ali Yikilmaz, Bo-Yee Ngan, Oscar M. Navarro
Pediatric Radiology.2015; 45(12): 1796. CrossRef

18,123 View
57 Download
6 Crossref

Original Article

Metachronous Double Primary Cancer after Diagnosis of Gastric Cancer: Jin Young Kim, Won Young Jang, Mi Hwa Heo, Kang Kuk Lee, Young Rok Do, Keon Uk Park, Hong Suk Song, Yoon Nyun Kim; Cancer Res Treat. 2012;44(3):173-178. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.173

Abstract PDF PubReader ePub

PURPOSE
The pattern of double primary cancers after treatment for gastric cancer is important for a patient's survival.
MATERIALS AND METHODS
We analyzed the clinicopathologic data of 214 gastric cancer patients from October 1996 to November 2007 with regard to metachronous second primary cancers.
RESULTS
Out of 5,778 patients with gastric cancer, metachronous second primary cancers occurred in 214 patients. The median age was 61.8 years, the number of male and female patients was 140 (65.4%), 74 (34.6%), respectively. The median time to the occurrence of second cancers after diagnosis of the first was 39.2 months (standard deviation, 31.2 months). The most common cancer was colorectal cancer, which occurred in 44 patients (20.6%), and lung cancer in 33 patients (15.4%), hepatocellular carcinoma in 26 patients (12.1%), ovarian cancer in 15 patients (7.0%), cervical cancer in 12 patients (7.0%), breast cancer in 11 patients (5.1%), and esophageal cancer in 11 patients (5.1%). The observed/expected (O/E) ratio showed a significant increase in colorectal (1.25), male biliary (1.60), ovarian (8.72), and cervical cancer (3.33) with primary gastric cancer. After five years from diagnosis of gastric cancer, secondary cancer occurred in 50 patients (23.4%), and breast cancer, prostate cancer, laryngeal cancer, lung cancer, and hepatocellular carcinoma were the most frequent.
CONCLUSION
The O/E ratio showed a significant increase in colorectal, male biliary, ovarian, and cervical cancer with primary gastric cancer, and second primary cancer as the main cause of death for these patients. A follow-up examination for metachronous double primary cancer is needed in order to improve the survival time in patients with gastric cancer.

Citations

Citations to this article as recorded by

Multiple Primary Malignancies in Patients With Gastric Cancer: A Retrospective Study in National Cancer Center of China
Guiling Zhu, Yutong Li, Bingzhi Wang, Liyan Xue, Yuchen Jiao, Xiaobing Wang, Chunxia Du
Cancer Innovation.2026;[Epub] CrossRef
Deciphering the risk of developing liver cancer following gastric cancer diagnosis with genetic evidence: a Mendelian randomization analysis in an East Asian population
Jiansheng Chen, Aiming Zeng, Yunzhe Yu, Liqun Liao, Siwei Huang, Sida Sun, Weijie Wu
Discover Oncology.2025;[Epub] CrossRef
Gastric Metastasis Mimicking Early Gastric Cancer from Invasive Ductal Carcinoma of the Breast: Case Report and Literature Review
Kwon Cheol Yoo, Dae Hoon Kim, Sungmin Park, HyoYung Yun, Dong Hee Ryu, Jisun Lee, Seung-Myoung Son
Medicina.2024; 60(6): 980. CrossRef
Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature
Makiko So, Aya Shimoji, Yoko Iemura, Ai Suizu, Shuichiro Iwami, Masahito Hoki, Shinsuke Shibuya
International Cancer Conference Journal.2024; 13(4): 427. CrossRef
Incidence and pattern of second primary cancer in patients diagnosed with primary cancer
Jong Sung, Ae Ahn, Ho Park, Kyu Jang, Woo Moon, Ju-Hyung Lee, Kyoung Kim, Myoung Chung
Oncology Letters.2024;[Epub] CrossRef
The risk and distribution of second primary cancers according to subsite of primary stomach cancer: a retrospective cohort population-based study
Ali Hemade, Souheil Hallit
Annals of Medicine & Surgery.2024; 86(12): 6944. CrossRef
Features of synchronous and metachronous dual primary gastric and colorectal cancer
Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
World Journal of Gastrointestinal Oncology.2023; 15(11): 1864. CrossRef
Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea
Jeong Ho Song, Yeonkyoung Lee, Jaesung Heo, Sang-Yong Son, Hoon Hur, Sang-Uk Han
Cancers.2022; 14(24): 6165. CrossRef
Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report
Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
BMC Gastroenterology.2021;[Epub] CrossRef
The contribution of second primary cancers to the mortality of patients with a gastric first primary cancer
Samantha Morais, Luís Antunes, Maria J. Bento, Nuno Lunet
European Journal of Gastroenterology & Hepatology.2019; 31(4): 471. CrossRef
Second Primary Cancer after Treating Gastrointestinal Cancer
Jeong Youp Park
The Korean Journal of Gastroenterology.2019; 74(4): 193. CrossRef
Gastric cancer and intrahepatic cholangiocarcinoma
Alex Emmanuel Elobu, Ashok Thorat, Vianney Kweyamba, Rakesh Rai
Formosan Journal of Surgery.2019; 52(3): 107. CrossRef
Occurrence of metachronous multiple primary cancers occurred in different parts of the stomach with 2 pathologic features
Yan Song, Ningning Zhao, Kui Jiang, Zhongqing Zheng, Bangmao Wang, Dalu Kong, Shu Li
Medicine.2018; 97(20): e10803. CrossRef
Surgical Strategy and Outcome in Patients Undergoing Pancreaticoduodenectomy After Gastric Resection: A Three‐Center Experience with 39 Patients
Dooin Lee, Jae Hoon Lee, Dongho Choi, Chang Moo Kang, Jae Uk Chong, Song‐Chul Kim, Kyeong Geun Lee
World Journal of Surgery.2017; 41(2): 552. CrossRef
Risk of second primary cancers among patients with a first primary gastric cancer: A population-based study in North Portugal
Samantha Morais, Luís Antunes, Maria José Bento, Nuno Lunet
Cancer Epidemiology.2017; 50: 85. CrossRef
Incidence of Gastric Cancer in Patients with Laryngeal Cancer
Ji-Hyun Seo, Hyun-Jin Kim, Jung Je Park, Ok-Jae Lee, Jin Pyeong Kim, Seong-Ki Ahn, Jeong Seok Hwa, Jong Sil Lee, Hee-Shang Youn
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(4): 190. CrossRef
Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan
San-Chi Chen, Chia-Jen Liu, Yu-Wen Hu, Chiu-Mei Yeh, Li-Yu Hu, Yen-Po Wang, Yi-Ping Hung, Cheng-Hwai Tzeng, Tzeon-Jye Chiou, Tzeng-Ji Chen, Chung-Jen Teng
Gastric Cancer.2016; 19(2): 490. CrossRef
Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan
Yi-Ping Hung, Chia-Jen Liu, Yu-Wen Hu, Min-Huang Chen, Chun-Pin Li, Chiu-Mei Yeh, Tzeon-Jye Chiou, Tzeng-Ji Chen, Muh-Hwa Yang, Yee Chao
Medicine.2015; 94(38): e1626. CrossRef
Role of Ki‐67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease
H. C. Miller, P. Drymousis, R. Flora, R. Goldin, D. Spalding, A. Frilling
World Journal of Surgery.2014; 38(6): 1353. CrossRef
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
Chan Kim, Hong Jae Chon, Beodeul Kang, Kiyeol Kim, Hei-Cheul Jeung, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
BMC Cancer.2013;[Epub] CrossRef

14,534 View
94 Download
20 Crossref

First
Prev
Page of 1
Next
Last

Search